Employees: 625
Size Gyre Therapeutics (GYRE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $500M, the 2669th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.34 on 18 Nov 2026.
Performance Over six months the shares fell 28.1%, against -18.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 13.5% over the last twelve months (peer median +9.4%); the operating margin is -18.1% (peer median 10.0%).
Valuation It trades at 4.0× enterprise value to sales against a peer median of 3.7× (10th most expensive of 20).
Capital Return on invested capital runs 28.8 points below its cost of capital (17.7% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $122M | $117M | $106M | $113M | $102M |
| Revenue growth | — | +10% | -7% | +11% | — |
| Gross profit | $115M | $111M | $102M | $109M | $97.5M |
| EBITDA | -$18.7M | $14.0M | $17.8M | $20.3M | $10.3M |
| Net income | -$25.1M | $5.03M | $12.1M | -$92.9M | $2.30M |
| Free cash flow | -$24.7M | -$1.67M | -$6.49M | $17.4M | $5.69M |
| Capital expenditure | $2.68M | $1.92M | $3.13M | $8.59M | $5.00M |
| Total debt | $3.01M | $939,000 | $1.60M | $409,000 | $613,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GYRE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.7% | -2.1% | lowest of 21 |
| 6-month return | -28.1% | -18.4% | 4th lowest of 21 |
| Distance from 52-week high | -52.5% | -35.5% | 4th lowest of 21 |
| Revenue growth (TTM) | +13.5% | +9.4% | 9th highest of 20 |
| Operating margin | -18.1% | 10.0% | 7th lowest of 20 |
| EV / Sales | 4.0× | 3.7× | 10th most expensive of 20 |
| ROIC minus cost of capital | -28.8 pp | -2.4 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |